AnaptysBio (ANAB) Competitors $19.29 +0.32 (+1.69%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$18.40 -0.89 (-4.61%) As of 04:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANAB vs. GMTX, EWTX, CNTA, KYMR, CGON, DNLI, BLTE, ARWR, ARQT, and TARSShould you be buying AnaptysBio stock or one of its competitors? The main competitors of AnaptysBio include Gemini Therapeutics (GMTX), Edgewise Therapeutics (EWTX), Centessa Pharmaceuticals (CNTA), Kymera Therapeutics (KYMR), CG Oncology (CGON), Denali Therapeutics (DNLI), Belite Bio (BLTE), Arrowhead Pharmaceuticals (ARWR), Arcutis Biotherapeutics (ARQT), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "pharmaceutical products" industry. AnaptysBio vs. Gemini Therapeutics Edgewise Therapeutics Centessa Pharmaceuticals Kymera Therapeutics CG Oncology Denali Therapeutics Belite Bio Arrowhead Pharmaceuticals Arcutis Biotherapeutics Tarsus Pharmaceuticals AnaptysBio (NASDAQ:ANAB) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk and media sentiment. Does the MarketBeat Community believe in ANAB or GMTX? AnaptysBio received 356 more outperform votes than Gemini Therapeutics when rated by MarketBeat users. Likewise, 66.25% of users gave AnaptysBio an outperform vote while only 63.33% of users gave Gemini Therapeutics an outperform vote. CompanyUnderperformOutperformAnaptysBioOutperform Votes37566.25% Underperform Votes19133.75% Gemini TherapeuticsOutperform Votes1963.33% Underperform Votes1136.67% Does the media refer more to ANAB or GMTX? In the previous week, AnaptysBio had 2 more articles in the media than Gemini Therapeutics. MarketBeat recorded 2 mentions for AnaptysBio and 0 mentions for Gemini Therapeutics. AnaptysBio's average media sentiment score of 0.35 beat Gemini Therapeutics' score of 0.00 indicating that AnaptysBio is being referred to more favorably in the media. Company Overall Sentiment AnaptysBio Neutral Gemini Therapeutics Neutral Do insiders and institutionals have more ownership in ANAB or GMTX? 75.4% of Gemini Therapeutics shares are owned by institutional investors. 33.7% of AnaptysBio shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts prefer ANAB or GMTX? AnaptysBio currently has a consensus price target of $35.11, indicating a potential upside of 82.02%. Given AnaptysBio's stronger consensus rating and higher probable upside, research analysts clearly believe AnaptysBio is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AnaptysBio 0 Sell rating(s) 4 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.75Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is ANAB or GMTX more profitable? Gemini Therapeutics has a net margin of 0.00% compared to AnaptysBio's net margin of -289.75%. Gemini Therapeutics' return on equity of -38.78% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets AnaptysBio-289.75% -287.94% -37.25% Gemini Therapeutics N/A -38.78%-35.88% Which has more volatility and risk, ANAB or GMTX? AnaptysBio has a beta of -0.1, meaning that its stock price is 110% less volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500. Which has stronger valuation & earnings, ANAB or GMTX? Gemini Therapeutics has lower revenue, but higher earnings than AnaptysBio. Gemini Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnaptysBio$91.28M6.48-$163.62M-$5.21-3.70Gemini TherapeuticsN/AN/A-$71.87M-$1.00-48.53 SummaryAnaptysBio beats Gemini Therapeutics on 12 of the 18 factors compared between the two stocks. Remove Ads Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANAB vs. The Competition Export to ExcelMetricAnaptysBioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$591.57M$6.73B$5.54B$7.49BDividend YieldN/A2.79%4.86%4.04%P/E Ratio-3.176.9923.2518.07Price / Sales6.48198.60361.2686.83Price / CashN/A65.6738.1634.64Price / Book5.815.926.493.99Net Income-$163.62M$142.37M$3.21B$247.18M7 Day Performance3.43%-9.32%-6.42%-6.42%1 Month Performance31.76%-10.26%-0.68%-7.44%1 Year Performance-6.90%-15.08%6.05%-4.31% AnaptysBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANABAnaptysBio1.8526 of 5 stars$19.29+1.7%$35.11+82.0%-6.9%$591.57M$91.28M-3.17100Gap DownGMTXGemini TherapeuticsN/A$52.24-1.9%N/A+51.5%$2.26BN/A-52.2430High Trading VolumeEWTXEdgewise Therapeutics1.8405 of 5 stars$23.37-1.0%$45.38+94.2%-26.6%$2.22BN/A-15.5860Analyst ForecastOptions VolumeNews CoverageCNTACentessa Pharmaceuticals2.8243 of 5 stars$16.63+5.6%$26.00+56.3%+20.7%$2.19B$6.85M-10.87200Gap DownKYMRKymera Therapeutics1.2553 of 5 stars$33.70+3.6%$56.36+67.2%-36.2%$2.19B$47.07M-14.40170News CoverageGap DownCGONCG Oncology1.1044 of 5 stars$28.53+5.5%$63.88+123.9%-51.2%$2.17B$684,000.000.0061Analyst RevisionNews CoverageGap DownDNLIDenali Therapeutics4.1925 of 5 stars$14.76+2.3%$37.20+152.0%-34.0%$2.14B$330.53M-5.35430News CoverageGap DownBLTEBelite Bio1.9601 of 5 stars$66.95-0.5%$96.33+43.9%+58.8%$2.13BN/A-60.3110ARWRArrowhead Pharmaceuticals3.175 of 5 stars$15.50+4.7%$41.44+167.4%-54.5%$2.13B$2.50M-3.00400Gap DownARQTArcutis Biotherapeutics2.552 of 5 stars$17.29+1.6%$18.80+8.7%+67.8%$2.05B$196.54M-9.66150Analyst ForecastNews CoverageGap DownTARSTarsus Pharmaceuticals2.696 of 5 stars$52.36+4.8%$63.67+21.6%+38.1%$2.01B$182.95M-13.7450Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies Gemini Therapeutics Competitors Edgewise Therapeutics Competitors Centessa Pharmaceuticals Competitors Kymera Therapeutics Competitors CG Oncology Competitors Denali Therapeutics Competitors Belite Bio Competitors Arrowhead Pharmaceuticals Competitors Arcutis Biotherapeutics Competitors Tarsus Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANAB) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ANAB Stock Free ANAB Stock Alerts